Eric Venker - 21 Jul 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Reporting relationship: President & Immunovant CEO
Issuer ticker: ROIV
Reported as of: 21 Jul 2025
Net transaction value: -$767,000
SEC form: 4
Accepted by SEC: 23 Jul 2025, 21:00:15 UTC
Prior SEC filing: 24 Jun 2025
Next SEC filing: 30 Jul 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker

Key filing fact

Eric Venker filed Form 4 for Roivant Sciences Ltd. (ROIV) on 23 Jul 2025.

Key facts

This page summarizes Eric Venker's Form 4 filing for Roivant Sciences Ltd. (ROIV).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jul 2025, 21:00.

Change

Previous filing in this sequence was filed on 24 Jun 2025.
Current net transaction value: -$767,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001801917 Primary reporting owner

Venker Eric

Relationship: President & Immunovant CEO
Address: C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Signature date: 23 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ROIV transaction

Common Shares

Options Exercise

Transaction value: $385,000
Shares: +100,000
Change %: +6.8%
Price: $3.85
Shares after: 1,562,223
Date: 21 Jul 2025
Ownership: Direct

ROIV transaction

Common Shares

Sale

Transaction value: $1,152,000
Shares: -100,000
Change %: -6.4%
Price: $11.52
Shares after: 1,462,223
Date: 21 Jul 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ROIV transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -100,000
Change %: -1.2%
Price: $0.000000
Shares after: 8,138,897
Date: 21 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $3.85
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Footnote F2

Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).